Amgen CEO Discusses Repatha Trial Results and Cholesterol Management
CNBC TelevisionDecember 5, 20252 min1,910 views
4 connections·5 entities in this video→Repatha Trial Data and LDL Cholesterol
- 💡 The trial demonstrated that lowering LDL cholesterol to a median of 45 reduced the risk of a first heart attack by 36%.
- 🎯 Adding Repatha on top of optimized therapy showed a 36% reduction in first heart attack occurrences.
- ⚡ The data also indicated a strong signal for preventing stroke and potentially cardiac death.
Key Findings on Cholesterol
- 🔑 It has been unequivocally demonstrated that lower LDL cholesterol is better.
- 📈 Even with a targeted median LDL of 45, a meaningful benefit was observed compared to the placebo group on previously considered optimal therapy.
- ⚠️ The study addressed long-standing questions for investigators, physicians, and patients regarding the benefits of aggressive LDL lowering.
Knowledge graph5 entities · 4 connections
How they connect
An interactive map of every person, idea, and reference from this conversation. Hover to trace connections, click to explore.
Hover · drag to explore
5 entities
Chapters1 moments
Key Moments
Transcript8 segments
Full Transcript
Topics9 themes
What’s Discussed
RepathaAmgenLDL CholesterolHeart Attack Risk ReductionStroke PreventionCardiac Death PreventionOptimized TherapyClinical Trial ResultsCholesterol Management
Smart Objects5 · 4 links
Product· 1
Concept· 1
Events· 3